Is Racial and Ethnic Representation in Oncology Clinical Trials Improving?

Health equity remains a critical priority in oncology, particularly ensuring that clinical trial enrollment accurately reflects the diverse populations impacted by cancer. Read the full accompanying article on Oncology Data Advisor: https://oncdata.com/racial-ethnic-representation-oncology-clinical-trials What You’ll Learn in This Episode: 🔹 AI Meets Trial Data: Understanding how multimodal large language models (LLMs) were utilized to automatically extract and evaluate three decades of demographic metrics from thousands of publication PDFs. 🔹 Exposing Enrollment Disparities: Analyzing why a dramatic tripling of trial demographic reporting has failed to translate into actual increased representation for Black and Hispanic communities in the US. 🔹 The Illusion of Global Progress: Exploring how international trial expansion, particularly in Asia, drives overall non-White participation data while domestic minority enrollment remains low or declines. 🔹 Structural Barriers to Participation: Evaluating the real-world operational and economic constraints—such as rigid follow-up schedules, travel distances, and dense language barriers—that hinder diverse patient accrual. 🔹 Fostering Equitable Research Environments: Actionable advice for investigators on leveraging pragmatic AI tools, like simplified consent language and patient-facing Q&A systems, to improve trial accessibility and trust. Chapter Timestamps: About the Speakers: Jiasheng Wang, MD, is an Assistant Professor of Hematology at The @OSUCCC_James – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. He specializes in the treatment of blood cancers with a holistic approach that considers each patient’s physical, mental, and social well-being. Waqas Haque, MD, MPH, is a second-year Hematology/Oncology Fellow at the@UChicago. His research focuses on innovative clinical trial design, value-based care delivery to cancer patients, and clinical investigation.